TrialBlood advances2022

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.

Marina Y Konopleva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.